Oktay Tutarel

Prof. Oktay Tutarel

1. Adult Congenital Heart Disease, Technical University of Munich, Munich, Germany
+3
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
OTOktay Tutarel
Oktay Tutarel
AKAleksander Kempny
Aleksander Kempny
RARafael Alonso-Gonzalez
Rafael Alonso-Gonzalez
RJRichard Jabbour
Richard Jabbour
WLWei Li
Wei Li
GDGerhard-Paul Diller
Gerhard-Paul Diller
Aims The population of adults with congenital heart disease (ACHD) is growing and ageing. Limited information about the diagnostic spectrum of this emerging population, its resource utilization at tertiary ACHD centres, and especially about prognostic parameters is available. Methods and results Retrospective cohort study on all ACHD patients ≥60 years of age under active follow-up. All-cause mortality was the primary outcome measure. Out of a total population of 7315 ACHD patients, 375 [190 females (50.7%), mean age 64.8 ± 5.9 years] fulfilled the inclusion criteria. During a median follow-up of 5.5 (IQR 3.1–8.6) years, 55 of the 375 patients died. The number of interventions ( P = 0.0006), the number and length of hospitalization ( P < 0.0001), and the number of outpatient clinic visits ( P < 0.0001) were significantly higher in patients ≥60 compared with patients aged between 20 and 60 years. Patients ≥60 years of age with moderate or severe congenital heart defects had worse survival prospects than their age- and gender-matched comparison population. On multivariate Cox analysis, coronary artery disease [hazard ratio (HR): 5.04; 95%CI: 1.88–13.51, P = 0.0014], symptoms of heart failure (HR: 2.36; 95%CI: 1.05–5.29, P < 0.05), NYHA class (HR: 1.96; 95%CI: 1.18–3.26, P < 0.01), and moderate to severe reduction in systemic ventricular systolic function (HR: 1.90; 95%CI: 1.20–2.99, P < 0.001) were the strongest prognostic factors. Conclusion There is a growing number of elderly ACHD patients with high mortality rates and a higher utilization of healthcare resources compared with younger patients. Acquired morbidities, such as coronary artery disease, seem to be key determinants of outcome in this older population in conjunction with the underlying congenital heart disease.

26 February 2013 in Circulation
Verified
Journal Article
Closed access
RARafael Alonso-Gonzalez
Rafael Alonso-Gonzalez
FBFrancesco Borgia
Francesco Borgia
GDGerhard-Paul Diller
Gerhard-Paul Diller
RIRyo Inuzuka
Ryo Inuzuka
AKAleksander Kempny
Aleksander Kempny
MGMichael A. Gatzoulis
Michael A. Gatzoulis
Background—: Restrictive lung defects are associated with higher mortality in patients with acquired chronic heart failure. We investigated the prevalence of abnormal lung function, its relation to severity of underlying cardiac defect, its surgical history, and its impact on outcome across the spectrum of adult congenital heart disease. Methods and Results—: A total of 1188 patients with adult congenital heart disease (age, 33.1±13.1 years) undergoing lung function testing between 2000 and 2009 were included. Patients were classified according to the severity of lung dysfunction based on predicted values of forced vital capacity. Lung function was normal in 53% of patients with adult congenital heart disease, mildly impaired in 17%, and moderately to severely impaired in the remainder (30%). Moderate to severe impairment of lung function related to complexity of underlying cardiac defect, enlarged cardiothoracic ratio, previous thoracotomy/ies, body mass index, scoliosis, and diaphragm palsy. Over a median follow-up period of 6.7 years, 106 patients died. Moderate to severe impairment of lung function was an independent predictor of survival in this cohort. Patients with reduced force vital capacity of at least moderate severity had a 1.6-fold increased risk of death compared with patients with normal lung function ( P =0.04). Conclusions—: A reduced forced vital capacity is prevalent in patients with adult congenital heart disease; its severity relates to the complexity of the underlying heart defect, surgical history, and scoliosis. Moderate to severe impairment of lung function is an independent predictor of mortality in contemporary patients with adult congenital heart disease.

1 May 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
CEClaudia C. Engelings
Claudia C. Engelings
PHPaul C. Helm
Paul C. Helm
HAHashim Abdul-Khaliq
Hashim Abdul-Khaliq
BABoulos Asfour
Boulos Asfour
UBUlrike M.M. Bauer
Ulrike M.M. Bauer
OTOktay Tutarel
Oktay Tutarel

2 February 2016 in European Heart Journal
Verified
Journal Article
Open access
PDF file
GDGerhard-Paul Diller
Gerhard-Paul Diller
MKMarc-André Körten
Marc-André Körten
UBUlrike M.M. Bauer
Ulrike M.M. Bauer
OMOliver Miera
Oliver Miera
OTOktay Tutarel
Oktay Tutarel
HBHelmut Baumgartner
Helmut Baumgartner
We aimed to assess the contemporary outcome of Eisenmenger syndrome (ES), delineate the use of disease targeting therapies (DTT) in these patients and to investigate the effect of treatment on outcome in the community. Patients with ES were systematically identified from the German National Register for Congenital Heart Defects. Data on underlying diagnosis, medical therapy, and survival were collected. The impact of DTT on survival was assessed using time-dependant Cox analysis. Overall, 153 ES patients were included (mean age 34.0 ± 13.3 years, 46% females). Of these, 88 (57.5%) were treated with at least one DTT (76.1% Bosentan, 20.5% Sildenafil) while 17.6% were on dual DTT. In addition, 24.8% of patients received digoxin, 10.5% angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers, and 17.6% β-blockers. Moreover, 17.6% of patients were treated with oral anticoagulants, while 23.5% of patients received Aspirin. The survival rate at 1, 5, and 10 years of follow-up was only 92, 75, and 57% in the entire cohort, and was even worse in treatment naive ES patients (survival rate 86, 60, and 34% at 1, 5, and 10 years). Use of DTT was independently associated with a better survival (hazard ratio 0.42, P= 0.015). This study illustrates the alarmingly poor survival prospects of Eisenmenger patients by community-based data even in the current era with advanced DTT and in a country with a wealthy health system. Treatment naive ES patients had especially high mortality rates approaching 60–70% at 10 years of follow-up. Treatment with DTT was associated with better survival.

28 July 2017 in Heart
Verified
Journal Article
Closed access
PDF file
OTOktay Tutarel
Oktay Tutarel
RARafael Alonso-Gonzalez
Rafael Alonso-Gonzalez
CMClaudia Montanaro
Claudia Montanaro
RSRenee Schiff
Renee Schiff
Aitor UribarriAitor Uribarri
Aitor Uribarri
MGMichael A Gatzoulis
Michael A Gatzoulis
Objective Infective endocarditis (IE) is associated with significant morbidity and mortality. Patients with adult congenital heart disease (ACHD) have an increased risk of developing IE. The aim of this study is to describe the incidence, predictors of outcome and mortality associated with IE in ACHD in a contemporary cohort. Methods All episodes of IE in adults with congenital heart disease referred to our tertiary centre between 1999 and 2013 were included in the study. Patients were identified from the hospital database. The diagnosis of endocarditis was established according to the modified Duke criteria. The primary endpoint of the study was endocarditis-associated mortality. Results There were 164 episodes of IE in 144 patients (male 102, 70.8%). Mean age at presentation was 32.3±22.7 years. Out of these, 43% had a simple, 23% a moderate and 32% a complex lesion. It was at least the second bout of IE in 37 episodes (23%). A predisposing event could be identified in only 26.2% of episodes. Surgical intervention during the same admission was performed in 61 episodes (37.2%). During a median follow-up of 6.7 years (IQR 2.9–11.4), 28 (19.4%) patients died. Out of these, 10 deaths were related to IE (IE mortality 6.9%). On unvariate regression analysis, the development of an abscess (OR: 7.23; 95% CI 1.81 to 28.94, p<0.01) and age (OR: 1.05; 95% CI 1.01 to 1.10, p=0.03) were the only predictors of IE-associated mortality. There was no increase in IE cases at our centre during the period of the study. Conclusions IE-associated morbidity and mortality in a contemporary cohort of ACHD patients is still high in the current era.

11 January 2018 in Heart
Verified
Journal Article
Closed access
PDF file
SKShelby Kutty
Shelby Kutty
DDDavid A Danford
David A Danford
GDGerhard-Paul Diller
Gerhard-Paul Diller
OTOktay Tutarel
Oktay Tutarel
Congenitally corrected transposition of the great arteries (ccTGA) can occur in isolation, or in combination with other structural cardiac anomalies, most commonly ventricular septal defect, pulmonary stenosis and tricuspid valve disease. Clinical recognition can be challenging, so echocardiography is often the means by which definitive diagnosis is made. The tricuspid valve and right ventricle are on the systemic arterial side of the ccTGA circulation, and are therefore subject to progressive functional deterioration. The natural history of ccTGA is also greatly influenced by the nature and severity of accompanying lesions, some of which require surgical repair. Some management strategies leave the right ventricle as the systemic arterial pump, but carry the risk of worsening heart failure. More complex ‘double switch’ repairs establish the left ventricle as the systemic pump, and include an atrial baffle to redirect venous return in combination with either arterial switch or Rastelli operation (if a suitable ventricular septal defect permits). Occasionally, the anatomic peculiarities of ccTGA do not allow straightforward biventricular repair, and Fontan palliation is a reasonable option. Regardless of the approach selected, late cardiovascular complications are relatively common, so ongoing outpatient surveillance should be established in an age-appropriate facility with expertise in congenital heart disease care.